Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II nivolumab with ipilimumab in relapsed lung cancer
2016-003334-25Phase 2Completed
- Sponsor
- University of Cologne
- Start
- Nov 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab and ipilimumab in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) (2 arms), sponsored by University of Cologne. Primary endpoint: Objective response rate. Started Nov 2016; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2016-003334-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003334-25.